Compare AbbVie Inc (ABBV) vs Uranium Energy Corp (UEC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Uranium Energy Corp — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Uranium Energy Corp trades at $9.96 (market cap $4.90B). The key difference: AbbVie Inc is far larger — about 91.8× Uranium Energy Corp's market cap, and AbbVie Inc pays a 2.72% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals.
| ABBV | UEC | |
|---|---|---|
Market Cap | $449.91B | $4.90B |
Sector | Health | Energy |
52-Week High | $261.07 | $20.14 |
52-Week Low | $184.85 | $5.92 |
Enterprise Value | $513.38B | $4.41B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
UEC trades at $10.57, down 2.22% today, amid bearish technical signals and weak quarterly results. The stock shows negative profitability with a -513.24% net income margin and has missed earnings expectations in two of the last three quarters. However, analyst sentiment remains strongly positive with 87.5% buy ratings, supported by the company's strategic positioning in uranium production and substantial liquidity of $794 million with no debt.
The outlook is mixed: strong analyst support and nuclear sector tailwinds offer long-term potential, but near-term risks include persistent losses, high valuation multiples, and operational execution challenges. Investors should weigh the company's asset base and market position against its current financial performance and cost pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
